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an update on the economic costs related to nonadherence to
antipsychotics. METHODS: A systematic MEDLINE search for
the years 1995–2004 was conducted to identify published
English-language articles on the economic impact of medication
nonadherence in schizophrenia. A manual search was also per-
formed using the references of retrieved articles to identify addi-
tional studies. For a study to be included, the direct healthcare
costs or the inpatient days related to nonadherence must have
been speciﬁcally assessed or estimated. We extracted data on
nonadherence rate, relapse rate, and inpatient days based on the
identiﬁed studies, and derived the daily hospital costs for schiz-
ophrenia in 2001 from National Inpatient Sample of Healthcare
Cost and Utilization Project. We then extrapolated the data to
national level to obtain an estimate on the inpatient costs related
to nonadherence to antipsychotics. RESULTS: A total of 7
studies were identiﬁed and assessed according to their study
design, measurement of medication nonadherence, study setting,
and cost outcome results. Although adherence measures varied
across studies, all the studies reviewed showed that nonadher-
ence to antipsychotic drugs was related to an increase in hospi-
talization rate, hospital days or hospital costs. Based on the
results from selected studies, we estimated that the national
rehospitalization costs related to nonadherence to antipsychotics
ranged approximately from $609 million to $979 million in year
2001. CONCLUSIONS: There is a consensus in the literature
that poor adherence to antipsychotic medications was associated
with higher risk of relapse and rehopitalization and higher 
hospitalization costs. Future investigations need to search more
effective interventions targeting speciﬁcally to nonadherent
patients to improve patient outcomes and reduce health care
costs.
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OBJECTIVES: To assess the duration of antipsychotic switching
process in the naturalistic treatment of schizophrenia.
METHODS: This post hoc analysis used data from a random-
ized, open-label, one-year trial of olanzapine, risperidone, and
typical antipsychotics in the treatment of schizophrenia (N =
664), in which switching of antipsychotics was permitted, when
clinically warranted. No suggestions were provided to clinicians
as to which switching strategy to use or how long the switch
process should last. The number of overlapping days between
antipsychotics during each switch was calculated for all switch-
ing episodes in the study (N = 217), by antipsychotic type
(typical, atypical), and by speciﬁc atypical antipsychotic (olan-
zapine, risperidone). RESULTS: Most of the switching between
antipsychotics (58.5%) was abrupt, with complete discontinua-
tion of the previous antipsychotic the same day or a day after
the start of the new antipsychotic. Abrupt switching was most
prevalent between the 2 atypical antipsychotics (75.9%), and
least prevalent when switching from any typical to atypical
antipsychotics (47.0%). The next most prevalent switching strat-
egy involved cross titration lasting 1–7 days (16.0%). CON-
CLUSIONS: Abrupt switching appears to be the most prevalent
antipsychotic switching strategy. Abrupt switching was previ-
ously found to provide outcomes comparable to other antipsy-
chotic switching strategies in the treatment of schizophrenia.
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OBJECTIVES: Depression is a prevalent psychiatric disorder
associated with impaired patient functioning and reductions in
health-related quality of life (HRQL). The present study
describes the impact of depression on patients’ HRQL and
assesses the impact of antidepressant treatment on HRQL.
METHODS: A total of 447 patients were recruited at 56 primary
care centres to this naturalistic longitudinal observational study.
Patients over 18 years with depressive symptoms, and who ini-
tiated a new antidepressant therapy were included in the study.
Data on patients’ socio-demographics, daily activity and quality-
of-life (EQ-5D) were collected using questionnaires completed
during outpatient GP visits for a follow-up period of 6 months.
Disease severity was assessed with the Clinical Global Impres-
sion Severity scale (CGI-S). Regression analysis was employed to
analyse the determinants of quality-of-life in depressed patients.
RESULTS: The mean EQ-5D utility score at baseline was 0.47
(0.44–0.49). Milder cases of depression reported a health utility
of 0.60, whereas moderately and severely depressed patients
reported utility values of 0.46 and 0.27 respectively (p < 0.001).
At end of follow-up the average utility in the sample was 0.69
(0.67–0.72), corresponding to an increase in utility by 0.23 over
6 months (p < 0.001). Our regression model showed that, all else
equal, patients who were on sickleave were associated with 10%
lower utility (p < 0.0001). Moreover, increased disease severity
(assessed with CGI) was associated with decreased health-related
quality of life. By treating the patient to achieve clinical remis-
sion is associated with higher quality of life and the presence 
of co-morbidity is associated with decreased quality-of-life.
CONCLUSIONS: Depression has a substantial impact on
health-related quality of life of the patient. Our results indicate
that antidepressants are associated with signiﬁcant improvement
in EQ-5D index score over a course of 6 months. Self-reported
patient valuations are important outcomes for cost-effectiveness
analysis of new antidepressant compounds.
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Despite the increased focus over the past decade suggesting that
full remission should be the primary goal of the treatment of
depression, there are few studies investigating the health eco-
nomic consequences of attaining remission in pharmacological
treatment in clinical practice. OBJECTIVE: The aim of this study
was to determine what impact full remission has on the cost and
health-related quality-of-life of depressed patients. METHODS:
Longitudinal data on patients’ socio-demographics, daily activ-
ity, health care resource use, quality-of-life (EQ-5D) were col-
lected using questionnaires completed during outpatient GP visit
for a follow-up period of approximately 6 months. Patient
recruitment and data collection were performed at about 56
primary care centres in Sweden and 447 patients were enrolled.
